VIATRIS INC. Gain (Loss) on Fair Value Hedges Recognized in Earnings
VIATRIS INC. (VTRS) reported Gain (Loss) on Fair Value Hedges Recognized in Earnings of -$82.70 million for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-07.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings · last filed 2022-11-07
- VIATRIS INC. gain (loss) on fair value hedges recognized in earnings for the quarter ending 2022-09-30 was -$82.70M, a 319.95% decline year-over-year.
- VIATRIS INC. gain (loss) on fair value hedges recognized in earnings for the quarter ending 2022-06-30 was $53.10M.
- VIATRIS INC. gain (loss) on fair value hedges recognized in earnings for the quarter ending 2022-03-31 was $21.70M, a 39.04% decline year-over-year.
- VIATRIS INC. gain (loss) on fair value hedges recognized in earnings for the quarter ending 2021-12-31 was -$19.00M.
- VIATRIS INC. gain (loss) on fair value hedges recognized in earnings for fiscal 2021 was $39.30M.
- VIATRIS INC. gain (loss) on fair value hedges recognized in earnings for fiscal 2020 was -$10.10M.
- VIATRIS INC. gain (loss) on fair value hedges recognized in earnings for fiscal 2019 was -$17.30M.
| Period end | Gain (Loss) on Fair Value Hedges Recognized in Earnings 3 month | Gain (Loss) on Fair Value Hedges Recognized in Earnings 6 month | Gain (Loss) on Fair Value Hedges Recognized in Earnings 9 month | Gain (Loss) on Fair Value Hedges Recognized in Earnings 12 month |
|---|---|---|---|---|
| 2022-09-30 | -$82.70M 10-Q · filed 2022-11-07 | -$29.60M derived: sum of 2 quarters · filed 2022-11-07 | -$7.90M 10-Q · filed 2022-11-07 | -$26.90M derived: sum of 4 quarters · filed 2022-11-07 |
| 2022-06-30 | $53.10M 10-Q · filed 2022-08-08 | $74.80M 10-Q · filed 2022-08-08 | $55.80M derived: sum of 3 quarters · filed 2022-08-08 | $93.40M derived: sum of 4 quarters · filed 2022-11-07 |
| 2022-03-31 | $21.70M 10-Q · filed 2022-05-09 | $2.70M derived: sum of 2 quarters · filed 2022-05-09 | $40.30M derived: sum of 3 quarters · filed 2022-11-07 | $25.40M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-12-31 | -$19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $18.60M derived: sum of 2 quarters · filed 2022-11-07 | $3.70M derived: sum of 3 quarters · filed 2022-11-07 | $39.30M 10-K · filed 2022-02-28 |
| 2021-09-30 | $37.60M 10-Q · filed 2022-11-07 | $22.70M derived: sum of 2 quarters · filed 2022-11-07 | $58.30M 10-Q · filed 2022-11-07 | $25.30M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$14.90M 10-Q · filed 2022-08-08 | $20.70M 10-Q · filed 2022-08-08 | -$12.30M derived: sum of 3 quarters · filed 2022-08-08 | -$2.50M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $35.60M 10-Q · filed 2022-05-09 | $2.60M derived: sum of 2 quarters · filed 2022-05-09 | $12.40M derived: sum of 3 quarters · filed 2022-05-09 | -$3.90M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$33.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$23.20M derived: sum of 2 quarters · filed 2022-02-28 | -$39.50M derived: sum of 3 quarters · filed 2022-02-28 | -$10.10M 10-K · filed 2022-02-28 |
| 2020-09-30 | $9.80M 10-Q · filed 2021-11-08 | -$6.50M derived: sum of 2 quarters · filed 2021-11-08 | $22.90M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | -$16.30M 10-Q · filed 2021-08-09 | $13.10M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $29.40M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | -$17.30M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |